Rachel Vatnsdal
Stock Analyst at JP Morgan
(4.46)
# 321
Out of 5,005 analysts
65
Total ratings
63.04%
Success rate
17.91%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HSIC Henry Schein | Maintains: Overweight | $80 → $76 | $67.03 | +13.38% | 4 | Aug 7, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $10 → $14 | $14.38 | -2.64% | 5 | Aug 6, 2025 | |
| AVTR Avantor | Maintains: Overweight | $17 → $14 | $14.29 | -2.03% | 1 | Aug 4, 2025 | |
| CAI Caris Life Sciences | Initiates: Overweight | $31 | $31.78 | -2.45% | 1 | Jul 14, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $12.75 | -29.41% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $31.07 | +6.21% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $148.73 | +27.75% | 6 | Apr 29, 2025 | |
| RVTY Revvity | Maintains: Neutral | $120 → $100 | $94.05 | +6.33% | 4 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $20.85 | -8.87% | 4 | Mar 6, 2025 | |
| WAT Waters | Maintains: Neutral | $380 → $390 | $328.39 | +18.76% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $55 | $91.66 | -40.00% | 3 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $62.84 | -12.48% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $160 | $141.64 | +12.96% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $670 | $543.32 | +23.32% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $8.06 | +148.14% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,314.04 | +6.54% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.49 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $36.98 | +143.37% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $214.99 | +25.59% | 4 | Dec 20, 2023 |
Henry Schein
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $76
Current: $67.03
Upside: +13.38%
Adaptive Biotechnologies
Aug 6, 2025
Maintains: Overweight
Price Target: $10 → $14
Current: $14.38
Upside: -2.64%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $17 → $14
Current: $14.29
Upside: -2.03%
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $31.78
Upside: -2.45%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $12.75
Upside: -29.41%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $31.07
Upside: +6.21%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $148.73
Upside: +27.75%
Revvity
Apr 29, 2025
Maintains: Neutral
Price Target: $120 → $100
Current: $94.05
Upside: +6.33%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $20.85
Upside: -8.87%
Waters
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $328.39
Upside: +18.76%
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $91.66
Upside: -40.00%
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $62.84
Upside: -12.48%
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $141.64
Upside: +12.96%
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $543.32
Upside: +23.32%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $8.06
Upside: +148.14%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,314.04
Upside: +6.54%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.49
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $36.98
Upside: +143.37%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $214.99
Upside: +25.59%